Mechanisms of disease: Polymorphisms of androgen regulatory genes in the development of prostate cancer

Nature Clinical Practice Urology

Volumn 2, Issue 2, 2005, Pages 101-107

  Singh, Arun S ^a   Chau, Cindy H ^b   Price, Douglas K ^b   Figg, William D ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Androgen receptor; Metabolism; Polymorphisms; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; ARGININE; CORTICOSTEROID DERIVATIVE; CYTOCHROME P450 17; CYTOCHROME P450 1B1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOSINE; FLUTAMIDE; GUANINE; MICROSATELLITE DNA; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER RISK; CARCINOGENESIS; DNA BINDING; DRUG BINDING SITE; DRUG RECEPTOR BINDING; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HORMONAL REGULATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; REGULATOR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TRINUCLEOTIDE REPEAT;

ANDROGENS; GENES, REGULATOR; HUMANS; MALE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 20344363167     PISSN: 17434270     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpuro0091     Document Type: Review

References (49)

1. Jemal A et al. (2004) Cancer statistics, 2004. CA Cancer J Clin 54: 8-29
2. Gelmann EP (2002) Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015
3. Irvine RA et al. (1995) The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 55: 1937-1940
4. Mhatre AN et al. (1993) Reduced transcriptional regulatory competence of the androgen receptor in X-linked spinal and bulbar muscular atrophy. Nat Genet 5: 184-188; erratum Nat Genet 6: 214
5. Chamberlain NL et al. (1994) The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 22: 3181-3186
6. Novelli G et al. (2004) Pharmacogenetics of human androgens and prostate cancer - an update. Pharmacogenomics 5: 283-294
7. Koivisto P et al. (1997) Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314-319
8. Marcelli M et al. (2000) Androgen receptor mutations in prostate cancer. Cancer Res 60: 944-949
9. Taplin ME et al. (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21: 2673-2678
10. Gottlieb B et al. (2004) The androgen receptor gene mutations database (ARDB): 2004 update. Hum Mutat 23: 527-533; erratum Hum Mutat 24: 102
11. Montgomery JS et al. (2001) The androgen receptor gene and its influence on the development and progression of prostate cancer. J Pathol 195: 138-146
12. Mononen N et al. (2000) Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 60: 6479-6481
13. Gruber SB et al. (2003) R726L androgen receptor mutation is uncommon in prostate cancer families in the United States. Prostate 54: 306-309
14. Ross RK et al. (1998) Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 58: 4497-4504
15. Taplin ME et al. (1995) Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332: 1393-1398
16. Taplin ME et al. (1999) Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59: 2511-2515
17. Feldman BJ and Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1: 34-45
18. James AJ et al. (2002) A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol 16: 2692-2705
19. Matias PM et al. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem 275: 26164-26171
20. Ntais C et al. (2003) Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12: 120-126
21. Habuchi T et al. (2000) Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effects. Cancer Res 60: 5710-5713
22. Wadelius M et al. (1999) Prostate cancer associated with CYP17 genotype. Pharmacogenetics 9: 635-639
23. Latil AG et al. (2001) Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 92: 1130-1137
24. Madigan MP et al. (2003) CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer 107: 271-275
25. Chang BL et al. (2003) Polymorphisms in the CYP1B1 gene are associated with increased risk of prostate cancer. Br J Cancer 89: 1524-1529
26. Ntais C et al. (2003) SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12: 618-624
27. Shimada T et al. (1999) Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20: 1607-1613
28. Tang YM et al. (2000) Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 10: 761-766
29. Tanaka Y et al. (2002) Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun 296: 820-826
30. Waxman DJ et al. (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steriod hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263: 424-436
31. Kleinbloesem CH et al. (1984) Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 33: 3721-3724
32. Rebbeck TR et al. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225-1229; erratum J Natl Cancer Inst 91: 1082
33. Ball SE et al. (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 66: 288-294
34. Kittles RA et al. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 110: 553-560
35. Zeigler-Johnson C et al. (2004) CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res 64: 8461-8467
36. Nam RK et al. (2003) Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 1429-1437
37. Gsur A et al. (2004) Genetic polymorphisms and prostate cancer risk. World J Urol 21: 414-423
38. Wojnowski L et al. (2002) Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 94: 630-631; author reply 631-632
39. Plummer SJ et al. (2003) CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 928-932
40. Cicek MS et al. (2004) Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR. Prostate 59: 69-76
41. Soderstrom T et al. (2002) 5 alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics 12: 307-312
42. Shibata A et al. (2002) Polymorphisms in the androgen receptor and type II 5 alpha-reductase genes and prostate cancer prognosis. Prostate 52: 269-278
43. Nam RK et al. (2001) V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology 57: 199-204
44. Makridakis NM et al. (1999) Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354: 975-978
45. Mononen N et al. (2001) A missense substitution A49T in the steriod 5- alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer 84: 1344-1347
46. Makridakis NM et al. (2000) Biochemical and pharmacogenetic dissection of human steroid 5 alpha-reductase type II. Pharmacogenetics 10: 407-413
47. Chang BL et al. (2002) Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 62: 1784-1789
48. Devgan SA et al. (1997) Genetic variation of 3 beta-hydroxysteroid dehydrogenase type II in three racial/ethnic groups: implications for prostate cancer risk. Prostate 33: 9-12
49. Rheaume E et al. (1995) Identification and characterization of the G15D mutation found in a male patient with 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3 beta-HSD. Biochemistry 34: 2893-2900